loading
前日終値:
$174.00
開ける:
$172.695
24時間の取引高:
7.00M
Relative Volume:
2.25
時価総額:
$22.10B
収益:
$4.29B
当期純損益:
$577.22M
株価収益率:
39.21
EPS:
4.2086
ネットキャッシュフロー:
$641.34M
1週間 パフォーマンス:
-26.35%
1か月 パフォーマンス:
-33.13%
6か月 パフォーマンス:
-46.69%
1年 パフォーマンス:
-63.30%
1日の値動き範囲:
Value
$163.30
$180.61
1週間の範囲:
Value
$163.30
$232.88
52週間の値動き範囲:
Value
$163.30
$479.79

Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile

Name
名前
Alnylam Pharmaceuticals Inc
Name
セクター
Healthcare (1052)
Name
電話
(617) 551-8200
Name
住所
675 WEST KENDALL STREET, CAMBRIDGE, MA
Name
職員
2,500
Name
Twitter
@alnylam
Name
次回の収益日
null
Name
最新のSEC提出書
Name
ALNY's Discussions on Twitter

Compare ALNY vs VRTX, REGN, MRNA, ARGX, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
165.00 22.10B 4.29B 577.22M 641.34M 4.2086
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
558.88 141.65B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
927.89 95.53B 14.92B 4.42B 3.79B 41.04
MRNA icon
MRNA
Moderna Inc
221.72 88.52B 2.23B -3.19B -1.60B -8.1462
ARGX icon
ARGX
Argen X Se Adr
892.87 56.15B 4.16B 1.29B 734.26M 19.58
ONC icon
ONC
Beone Medicines Ltd Adr
370.33 41.89B 5.76B 514.49M 1.10B 4.4813

Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-10-15 再開されました UBS Buy
2026-08-19 開始されました BMO Capital Markets Outperform
2026-08-03 アップグレード Raymond James Outperform → Strong Buy
2026-05-19 開始されました Citigroup Buy
2026-03-16 ダウングレード Jefferies Buy → Hold
2026-01-28 再開されました Barclays Overweight
2026-01-07 再開されました Oppenheimer Outperform
2025-08-04 アップグレード Oppenheimer Perform → Outperform
2025-08-04 アップグレード Wolfe Research Underperform → Peer Perform
2025-07-30 再開されました Raymond James Outperform
2025-07-21 開始されました Truist Buy
2025-03-31 開始されました Redburn Atlantic Buy
2025-03-24 アップグレード JP Morgan Neutral → Overweight
2024-11-12 ダウングレード Wolfe Research Peer Perform → Underperform
2024-10-16 開始されました Scotiabank Sector Outperform
2024-08-16 アップグレード Goldman Neutral → Buy
2024-02-16 ダウングレード Goldman Buy → Neutral
2024-02-15 開始されました Wolfe Research Peer Perform
2023-12-08 開始されました Wells Fargo Equal Weight
2023-10-11 ダウングレード Oppenheimer Outperform → Perform
2023-09-29 開始されました Raymond James Outperform
2023-05-05 アップグレード BMO Capital Markets Market Perform → Outperform
2023-04-26 開始されました SMBC Nikko Neutral
2023-03-21 開始されました Bernstein Outperform
2023-01-18 開始されました Canaccord Genuity Buy
2022-09-09 再開されました Morgan Stanley Equal-Weight
2022-07-13 開始されました Cantor Fitzgerald Neutral
2022-06-27 ダウングレード Guggenheim Buy → Neutral
2022-06-07 開始されました William Blair Outperform
2022-04-25 ダウングレード Morgan Stanley Overweight → Equal-Weight
2022-03-01 開始されました Citigroup Buy
2022-02-03 アップグレード Guggenheim Neutral → Buy
2022-01-03 アップグレード Piper Sandler Neutral → Overweight
2021-11-22 アップグレード Goldman Neutral → Buy
2021-11-22 アップグレード RBC Capital Mkts Sector Perform → Outperform
2021-11-01 アップグレード Oppenheimer Perform → Outperform
2021-10-04 アップグレード UBS Neutral → Buy
2021-08-04 ダウングレード Piper Sandler Overweight → Neutral
2021-02-22 ダウングレード Guggenheim Buy → Neutral
2021-02-12 ダウングレード Citigroup Buy → Neutral
2021-02-12 繰り返されました H.C. Wainwright Buy
2021-01-25 ダウングレード BMO Capital Markets Outperform → Market Perform
2020-09-30 再開されました Berenberg Hold
2020-09-08 開始されました Citigroup Buy
2020-08-11 ダウングレード Oppenheimer Outperform → Perform
2020-05-13 開始されました RBC Capital Mkts Sector Perform
2020-05-07 ダウングレード JP Morgan Overweight → Neutral
2020-04-24 再開されました Evercore ISI Outperform
2020-03-19 開始されました Berenberg Buy
2019-12-19 繰り返されました Chardan Capital Markets Buy
2019-11-20 開始されました Oppenheimer Outperform
2019-11-13 開始されました BofA/Merrill Buy
2019-05-23 再開されました Goldman Neutral
2019-04-12 開始されました Evercore ISI Outperform
2019-03-06 アップグレード Evercore ISI In-line → Outperform
2019-03-05 アップグレード Morgan Stanley Equal-Weight → Overweight
2019-01-23 開始されました UBS Neutral
2018-10-01 開始されました Cantor Fitzgerald Overweight
2018-08-13 繰り返されました Stifel Buy
2018-08-07 アップグレード Stifel Hold → Buy
2018-05-04 繰り返されました Stifel Hold
2018-03-28 開始されました Evercore ISI In-line
すべてを表示

Alnylam Pharmaceuticals Inc (ALNY) 最新ニュース

pulisher
Oct 29, 2026

Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top Estimates - Zacks Investment Research

Oct 29, 2026
pulisher
Oct 27, 2026

UBS cuts target for Alnylam Pharmaceuticals stock from USD 550.00 to USD 354.00 - ad-hoc-news.de

Oct 27, 2026
pulisher
Oct 26, 2026

Alnylam Reports Up to 83% Huntingtin Reduction, Eyes 2027 Pivotal Trial - TradingView

Oct 26, 2026
pulisher
Oct 26, 2026

Alnylam Reports Up to 83% Huntingtin Reduction, Eyes 2027 Pivotal Trial - Yahoo Finance

Oct 26, 2026
pulisher
Oct 26, 2026

Alnylam Reports Up to 83% Huntingtin Reduction, Eyes 2027 Pivotal Trial - TradingView

Oct 26, 2026
pulisher
Oct 26, 2026

Alnylam Pharmaceuticals, Inc.- RNAi Roundtable Transcript - GuruFocus

Oct 26, 2026
pulisher
Oct 26, 2026

Alnylam: Amvuttra Growth And Brezosiran Strengthen The Bull Case (NASDAQ:ALNY) - Seeking Alpha

Oct 26, 2026
pulisher
Oct 26, 2026

Analysts Estimate Krystal Biotech, Inc. (KRYS) to Report a Decline in Earnings: What to Look Out for - Zacks Investment Research

Oct 26, 2026
pulisher
Oct 25, 2026

Alnylam Pharmaceuticals Inc. Research & Ratings | ALNY - Barron's

Oct 25, 2026
pulisher
Oct 23, 2026

Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Hun - Alnylam

Oct 23, 2026
pulisher
Oct 23, 2026

Alnylam Lobbying Rises Amid Medicare Drug Pricing Debate - Legis1

Oct 23, 2026
pulisher
Oct 23, 2026

Alnylam Pharmaceuticals (ALNY) Reports Promising Phase 1b Results for Huntington's Disease Therapy - GuruFocus

Oct 23, 2026
pulisher
Oct 23, 2026

Alnylam Pharmaceuticals, Inc. Estimates – NASDAQ:ALNY - TradingView

Oct 23, 2026
pulisher
Oct 23, 2026

Alnylam Pharmaceuticals (ALNY) Reports Promising Phase 1b Data f - GuruFocus

Oct 23, 2026
pulisher
Oct 22, 2026

Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs | DelveInsight - GlobeNewswire Inc.

Oct 22, 2026
pulisher
Oct 22, 2026

Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Zacks Investment Research

Oct 22, 2026
pulisher
Oct 22, 2026

Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance

Oct 22, 2026
pulisher
Oct 22, 2026

Alnylam Pharmaceuticals (ALNY) Cuts 2026 Guidance After AMVUTTRA Sales Beat, Is It Fully Valued - Simply Wall Street

Oct 22, 2026
pulisher
Oct 21, 2026

Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech? - Yahoo Finance

Oct 21, 2026
pulisher
Oct 21, 2026

Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech? - The Motley Fool

Oct 21, 2026
pulisher
Oct 20, 2026

Alnylam (ALNY): Can the RNAi Franchise Get it an Entry into the S&P 500 Index? - Yahoo Finance

Oct 20, 2026
pulisher
Oct 19, 2026

Alnylam to Present New Data Reinforcing Strength in RNAi-Powered - The National Law Review

Oct 19, 2026
pulisher
Oct 18, 2026

ALNYLAM PHARMACEUTICALS INC (ALNY.MX) Q4 FY2025 earnings call transcript - Yahoo Finance

Oct 18, 2026
pulisher
Oct 17, 2026

What Has Changed For Alnylam Pharmaceuticals Since Its 52% Fall - Simply Wall Street

Oct 17, 2026
pulisher
Oct 16, 2026

Alnylam Pharmaceuticals, Inc. (ALNY) Stock Forecasts - Yahoo Finance

Oct 16, 2026
pulisher
Oct 16, 2026

Alnylam Pharmaceuticals (NASDAQ:ALNY): Affordable Growth With RNAi Commercial Momentum - ChartMill

Oct 16, 2026
pulisher
Oct 16, 2026

Alnylam Pharmaceuticals, Inc. (ALNY) options chain - Yahoo Finance Australia

Oct 16, 2026
pulisher
Oct 15, 2026

UBS Adjusts Alnylam Pharmaceuticals Price Target to $354 From $550, Maintains Buy Rating - Yahoo Finance

Oct 15, 2026
pulisher
Oct 15, 2026

Alnylam to Webcast Conference Call Discussing Third Quarter 2026 Financial Results - Alnylam

Oct 15, 2026
pulisher
Oct 14, 2026

Alnylam Pharmaceuticals (NASDAQ:ALNY) Share Price, Forecast & Analysis - Stocks Down Under

Oct 14, 2026
pulisher
Oct 14, 2026

Alnylam Pharmaceuticals (ALNY) vs. IONS and ARWR: Can Pipeline Growth Restore Confidence After the Guidance Cut? - Yahoo Finance

Oct 14, 2026
pulisher
Oct 12, 2026

Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why - Zacks Investment Research

Oct 12, 2026
pulisher
Oct 12, 2026

PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know - Zacks Investment Research

Oct 12, 2026
pulisher
Oct 09, 2026

argenx Meets Primary Endpoint in Phase II Celiac Disease Study - Zacks Investment Research

Oct 09, 2026
pulisher
Oct 09, 2026

EDIT Set to Begin First-in-Human Study in Hypercholesterolemia - Zacks Investment Research

Oct 09, 2026
pulisher
Oct 09, 2026

BofA Securities Adjusts Alnylam Pharmaceuticals Price Target to $336 From $346 - Yahoo Finance

Oct 09, 2026
pulisher
Oct 09, 2026

Alnylam Pharmaceuticals (ALNY) Stock Looks Pricey Despite A 51% Slide - Yahoo Finance

Oct 09, 2026
pulisher
Oct 08, 2026

Here's Why You Should Add LPCN Stock to Your Portfolio Now - Zacks Investment Research

Oct 08, 2026
pulisher
Oct 08, 2026

Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash - Zacks Investment Research

Oct 08, 2026
pulisher
Oct 08, 2026

Alnylam Pharmaceuticals (ALNY) Looks Undervalued On Paper, Can Its RNAi Pipeline Support Fair Value? - Yahoo Finance

Oct 08, 2026
pulisher
Oct 07, 2026

ETON Stock Surges 108% in Six Months: Here's What You Need to Know - Zacks Investment Research

Oct 07, 2026
pulisher
Oct 06, 2026

PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal - Zacks Investment Research

Oct 06, 2026
pulisher
Oct 05, 2026

Type 2 Diabetes Market to Grow Significantly During the Forecast Period (2026–2036), with Rising Prevalence and Increasing Uptake of Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.

Oct 05, 2026
pulisher
Oct 05, 2026

Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm - GlobeNewswire Inc.

Oct 05, 2026
pulisher
Oct 05, 2026

Securities Fraud Investigation Into Alnylam - GlobeNewswire

Oct 05, 2026
pulisher
Oct 05, 2026

Securities Fraud Investigation Into Alnylam - GlobeNewswire

Oct 05, 2026
pulisher
Oct 05, 2026

Alnylam Pharmaceuticals Stock: 5 Straight Red Days, Down 14% - Trefis

Oct 05, 2026
pulisher
Oct 03, 2026

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Peri - Alnylam

Oct 03, 2026
pulisher
Oct 02, 2026

Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - wboc.com

Oct 02, 2026
pulisher
Oct 02, 2026

Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - GlobeNewswire

Oct 02, 2026

Alnylam Pharmaceuticals Inc (ALNY) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Alnylam Pharmaceuticals Inc (ALNY) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
SUPRAN BRYAN
Officer
Oct 02 '26
Proposed Sale
226.88
1,758
398,862
0
PYOTT DAVID E I
Director
Jun 01 '26
Sale
299.18
3,830
1,145,853
1,582
PYOTT DAVID E I
Director
Jun 01 '26
Option Exercise
0.00
3,830
0
5,412
PYOTT DAVID E I
Director
Jun 01 '26
Proposed Sale
299.51
3,830
1,147,123
0
SCHULMAN AMY W
Director
May 13 '26
Option Exercise
70.20
11,250
789,750
23,211
McLaughlin Melissa
Officer
Apr 06 '26
Proposed Sale
320.10
2,286
731,749
0
McLaughlin Melissa
Chief Human Resources Officer
Apr 06 '26
Sale
330.42
2,286
755,329
9,443
McLaughlin Melissa
Chief Human Resources Officer
Apr 02 '26
Sale
319.59
1,624
519,014
11,729
Fitzgerald Kevin Joseph
CSO & EVP, Head of Research
Mar 05 '26
Sale
323.98
658
213,177
20,569
Fitzgerald Kevin Joseph
Officer
Mar 05 '26
Proposed Sale
323.69
658
212,988
0
$88.17
price down icon 1.08%
$120.39
price up icon 3.07%
$112.58
price up icon 0.89%
$36.91
price down icon 1.63%
$69.39
price up icon 4.82%
$251.27
price down icon 0.68%
大文字化:     |  ボリューム (24 時間):